Search Results

Bio-Techne Corporation announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer monitoring, resolving conventionally inaccessible, disease-causing genes, and more at the upcoming meeting of the Association for Molecular Pathology, to be held November 14-18 in Salt Lake City, Utah.

Bio-Techne Corporation (NASDAQ: TECH) today announced that Asuragen, a Bio-Techne brand, will present its diagnostic lab solutions at the upcoming annual meeting of the Association for Molecular Pathology (AMP), taking place November 1-5 in Phoenix, Ariz.

Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones.

Bio-Techne Corporation announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene.

Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Asuragen

Feb. 24, 2020 13:00 UTC FDA Grants Premarket Clearance of Asuragen’s AmplideX ® Fragile X Dx and Carrier Screen Kit The first IVD for the diagnosis and screening of fragile X syndrome and other FMR1-related disorders AUSTIN, Texas--( BUSINESS WIRE )-- Asuragen, Inc. , a molecular diagnostics company delivering high-quality, easy-to-use products for complex testing in genetics and oncology, today announced that its AmplideX ® Fragile X Dx and Carrier Screen Kit has been c